Inovio Pharmaceuticals
INO
133 hedge funds and large institutions have $32.1M invested in Inovio Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 44 reducing their positions, and 63 closing their positions.
2,183% more call options, than puts
Call options by funds: $274K | Put options by funds: $12K
1.63% less ownership
Funds ownership: 3.9% → 2.27% (-1.6%)
24% less funds holding
Funds holding: 174 → 133 (-41)
41% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 44
60% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 63
68% less capital invested
Capital invested by funds: $99.8M → $32.1M (-$67.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.59M |
| 2 |
Renaissance Technologies
New York
|
+$1.88M |
| 3 |
Jane Street
New York
|
+$1.52M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
| 5 |
Two Sigma Investments
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.2M |
| 2 |
BlackRock
New York
|
-$11.5M |
| 3 |
Rafferty Asset Management
New York
|
-$2.17M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.92M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.78M |
INO Hedge Fund Activity: Q2 2023 in Review
133 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2023, worth a combined $32.1M — down 68% from $99.8M a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of INO and 25 opened new positions — a net loss of 38 holders — while 44 trimmed existing stakes and 26 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.59M. The largest seller was State Street, cutting an estimated $18.2M.
- 133 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2023, down from 174 in Q1 2023.
- Funds reported $32.1M of Inovio Pharmaceuticals stock for Q2 2023, down 68% quarter-over-quarter.
- 25 funds opened new Inovio Pharmaceuticals positions in Q2 2023 and 63 closed out, a net change of -38 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2023 was Millennium Management, an estimated $3.59M added.
- The largest Inovio Pharmaceuticals seller in Q2 2023 was State Street, an estimated $18.2M sold.
Based on aggregated 13F filings for Q2 2023.